Get the Stockscreener App
84.17
2.57%
-1.59
Soleno Therapeutics Inc stock is traded at $84.17, with a volume of 129.52K.
It is down -2.57% in the last 24 hours and up +2.44% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$85.76
Open:
$85.82
24h Volume:
129.52K
Relative Volume:
0.12
Market Cap:
$4.48B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-28.09
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+2.36%
1M Performance:
+2.44%
6M Performance:
+66.28%
1Y Performance:
+78.39%
1-Day Range:
$82.90
$86.34
1-Week Range:
$77.33
$87.17
52-Week Range:
$41.50
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
84.27 | 4.38B | 0 | -38.99M | -24.94M | -2.9966 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.27 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.36 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.35 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.80 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
287.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Initiated | TD Cowen | Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
| Dec-02-24 | Reiterated | Stifel | Buy |
| Sep-03-24 | Initiated | H.C. Wainwright | Buy |
| May-10-24 | Initiated | Robert W. Baird | Outperform |
| Feb-05-24 | Initiated | Piper Sandler | Overweight |
| Jan-23-24 | Initiated | Stifel | Buy |
| Nov-21-23 | Resumed | Guggenheim | Buy |
| Sep-29-20 | Initiated | Guggenheim | Buy |
| Jan-10-20 | Initiated | Craig Hallum | Buy |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
What is the long term forecast for Soleno Therapeutics Inc. stockWealth Creation Plan With Stocks - thegnnews.com
Soleno Therapeutics Inc. Chart Enters High Volatility ZoneAI Driven Buy Alert Trade Blueprint Released - metal.it
How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% - Yahoo Finance
Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going - Yahoo Finance
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - ADVFN Brasil
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Stifel raises Soleno Therapeutics stock price target to $118 on strong launch - Investing.com Nigeria
Soleno Therapeutics price target raised to $120 from $115 at TD Cowen - TipRanks
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales By Investing.com - Investing.com South Africa
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales - Investing.com Australia
Earnings call transcript: Soleno Therapeutics beats Q2 2025 forecasts with strong revenue - Investing.com
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations - AInvest
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
Soleno Therapeutics Reports Strong Q2 2025 Performance - TipRanks
Soleno Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Soleno Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand - TipRanks
Soleno (SLNO) Q2 Revenue Jumps 30% - The Motley Fool
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Soleno Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soleno Therapeutics earnings beat by $0.55, revenue topped estimates - Investing.com Canada
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch By Investing.com - Investing.com South Africa
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch - Investing.com Nigeria
Soleno Therapeutics Q2 2025 Financial Results and VYKAT XR Launch Update - TradingView
Soleno Therapeutics Q2 net loss $4.7 mln - MarketScreener
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q2 Revenue $32.7M, vs. FactSet Est of $25.1M - MarketScreener
Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan
When Will Soleno Therapeutics, Inc. (NASDAQ:SLNO) Become Profitable? - 富途牛牛
Is Soleno Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
When is Soleno Therapeutics Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What makes Soleno Therapeutics Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
What are analysts’ price targets for Soleno Therapeutics Inc. in the next 12 monthsUnmatched market gains - Jammu Links News
How does Soleno Therapeutics Inc. compare to its industry peersRealize exceptional returns through smart trading - Jammu Links News
What is the risk reward ratio of investing in Soleno Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
Should I hold or sell Soleno Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
What are the latest earnings results for Soleno Therapeutics Inc.Unlock powerful portfolio management tools - Jammu Links News
How does Soleno Therapeutics Inc. generate profit in a changing economyExplosive trading growth - Jammu Links News
Soleno Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What catalysts could drive Soleno Therapeutics Inc. stock higher in 2025Stay ahead with daily market updates - Jammu Links News
What analysts say about Soleno Therapeutics Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What machine learning models say about Soleno Therapeutics Inc.Fast Gaining Stock Screener Reports Released - metal.it
How Soleno Therapeutics Inc. stock performs during market volatilityWeekly Watchlist of High Movers Released - beatles.ru
Live Scanner Shows Breakout on Soleno Therapeutics Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET - The Globe and Mail
What does SLNO's flat EPS in 2024 indicate for future growth? - AInvest
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):